Belimumab in systemic lupus erythematosus: Experience in clinical practice settings in a regional hospital

作者：L. Riancho-Zarrabeitia, Ignacio Villa Blanco, M. Santos-Gómez, E. Aurrecoechea · 发表于：Reumatología Clínica (English Edition) · 年份：2020 · DOI：10.1016/j.reumae.2018.02.005 · 被引用次数：2 · 研究领域：Medicine

1. Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73:86–94. 2. Genovese MC, Tena CP, Covarrubias A, Leon G, Mysler E, Keiserman M, et al. Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial. J Rheumatol. 2014;41:629–39. 3. Keystone EC, Kremer JM, Russell A, Box J, Abud-Mendoza C, Elizondo MG, et al. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. Ann Rheum Dis. 2012;71:857–61. 4. Reggia R, Franceschini F, Tincani A, Cavazzana I. Switching from intravenous to subcutaneous formulation of abatacept: a single-center Italian experience on efficacy and safety. J Rheumatol. 2015;42:193–5.